Related Experiment Video
Updated: Jan 1, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice
Jozefina Casuscelli1, Yann-Alexandre Vano2,3, Wolf Herve Fridman3
1Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Abstract:
Renal cell carcinoma (RCC) encompasses a wide spectrum of morphologically and molecularly distinct (>10) cancer subtypes originated from the kidney epithelium. Metastatic RCC (mRCC) is lethal and refractory to conventional chemotherapeutic agents. The incorporation of targeted therapies and immune checkpoint inhibitors into the current practice of mRCC has markedly improved the median overall survival of clear cell RCC (ccRCC) patients, the most common subtype, but not rare kidney cancer (RKC or non-ccRCC, nccRCC). Varied treatment response in mRCC patients is observed, which presents clinical challenges/opportunities at the modern mRCC therapeutic landscape consisting of 12 approved drugs representing 6 different effective mechanisms. Key contributing factors include inter- and intra-RCC heterogeneity. With the advances in pan-omics technologies, we now have a better understanding of the molecular pathobiology of individual RCC subtype. Here, we attempt to classify ccRCC based on contemporary molecular features with emphasis on their respective potential significance in clinical practice.
Insights
Renal cell carcinoma (RCC) is diverse, with clear cell RCC (ccRCC) benefiting from new therapies. Rare kidney cancers (RKC) still need better treatments due to molecular heterogeneity.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) comprises over 10 distinct kidney cancer subtypes.
- Metastatic RCC (mRCC) is often lethal and resistant to chemotherapy.
- Targeted therapies and immunotherapies have improved survival for clear cell RCC (ccRCC) but not rare kidney cancers (RKC).
Purpose of the Study:
- To classify ccRCC based on current molecular features.
- To explore the clinical significance of these molecular classifications for ccRCC treatment.
Main Methods:
- Utilizing advances in pan-omics technologies.
- Analyzing molecular pathobiology of individual RCC subtypes.
- Focusing on contemporary molecular features for classification.
Main Results:
- Identified key molecular features contributing to inter- and intra-RCC heterogeneity.
- Highlighted varied treatment responses in mRCC patients.
- Provided a molecular basis for understanding ccRCC diversity.
Conclusions:
- Molecular classification of ccRCC is crucial for personalized treatment strategies.
- Understanding heterogeneity is key to improving outcomes for all RCC subtypes.
- Further research into RKC molecular drivers is needed for therapeutic advancements.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
